GPR75 Antagonist Compounds for Cardiovascular and Renal Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current 20-HETE antagonists exhibit undesirable pharmacological profiles, including poor solubility, rapid metabolism, and low efficacy, and the receptor through which 20-HETE signaling occurs has not been identified, limiting their effectiveness in treating cardiovascular and renal diseases.
Innovation Solution
Development of novel compounds with 20-HETE antagonist activity that target the previously unknown receptor GPR75, providing improved pharmacological profiles such as biostability, bioavailability, and potency, and methods for identifying these antagonists for treating cardiovascular, cerebral, and renal diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If previously identified 20-HETE antagonists are used, then 20-HETE signaling can be blocked, but the compounds exhibit poor solubility, rapid metabolism, and low efficacy
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of 20-HETE analogs, specifically varying the hydroxyl group positions (19-HETE, 20-HETE, 21-HETE) and chain lengths to optimize both solubility and efficacy. The compounds of Formula I and II represent structured parameter variations that improve pharmacological properties while maintaining 20-HETE antagonist activity.
Solution Approach 2:
The invention creates composite molecular structures by combining the eicosanoid backbone with specific hydroxyl substitutions and carboxylic acid groups, forming compounds that integrate multiple functional elements. This composite approach allows the molecules to achieve both adequate solubility and high antagonist efficacy simultaneously.
2Reliability
If previously identified 20-HETE antagonists are used, then 20-HETE signaling can be blocked, but the compounds are chemically labile and rapidly metabolized
Solution Approach 1:
The patent employs parameter changes by systematically varying the position of hydroxyl groups (at carbons 19, 20, or 21) and the length of the carbon chain to enhance chemical stability. These parameter modifications result in compounds with improved resistance to metabolism while maintaining biological activity.
Solution Approach 2:
The invention converts the typically harmful rapid metabolism into a benefit by designing compounds where controlled metabolic pathways lead to stable metabolites or where the metabolic resistance itself provides prolonged therapeutic action. The structured analogs are designed to withstand metabolic degradation better than natural 20-HETE.
Data Source
AI summary
The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.